Molecular engineering company Scribe Therapeutics Inc announced on Tuesday a new research collaboration with French healthcare company Sanofi SA (Euronext Paris: SAN) (NASDAQ: SNY).
Under the agreement Sanofi will use Scribe's CRISPR genome editing technologies to enable genetic modification of novel natural killer (NK) cell therapies for cancer.
Sanofi is granted non-exclusive rights to Scribe's CasX-Editor (XE) technology for multiple oncology targets in exchange for a USD25m upfront fee with the potential for more than USD1bn in milestone payments, as well as tiered royalties on net future sales of any products that may result from this research agreement.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study